araag2/HINT huggingface dataset:
Clinical trial NCT00230178 (phase 3, status: completed)
Conditions: tumor lysis syndrome, cancer, hyperuricemia
ICD codes: E88.3, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, E79.0
Drugs: rasburicase (sr29142), allopurinol
SMILES: O=C1N=CN=C2NNC=C12
Eligibility criteria:

        Inclusion Criteria:

          1. Meets high risk or at potential risk for tumor lysis syndrome (TLS):

             A patient is at high risk for TLS if he/she presents with:

               -  Hyperuricemia of malignancy (plasma uric acid > 7.5 mg/dL);

               -  A diagnosis of very aggressive lymphoma/leukemia based on the Revised
                  European-American Lymphoma (REAL) classification of lymphoma/leukemia;

               -  Acute myeloid leukemia (AML);

               -  Chronic myeloid leukemia (CML) in blast crisis; or

               -  High grade myelodysplastic syndrome (refractory anemia with excess blast, chronic
                  myelomonocytic leukemia, and refractory anemia with excess blast in
                  transformation) only if they have > 10% bone marrow blast involvement and are
                  given aggressive treatment similar to AML.

             A patient is at potential risk for TLS if he/she presents with:

               -  A diagnosis of aggressive lymphoma/leukemia based on the REAL classification of
                  lymphoma/leukemia plus 1 or more of the following criteria:

                    -  Lactate dehydrogenase (LDH) >= 2 x upper limit of normal (ULN) (IU/L)

                    -  Stage III-IV disease

                    -  Stage I-II disease with at least 1 lymph node/tumor > 5 cm in diameter

             In addition to the above-mentioned eligibility criteria, the patients should have the
             following criteria:

          2. Eastern Cooperative Oncology Group (ECOG) performance status 0-3

          3. Age >= 18 years

          4. Life expectancy > 3 months

          5. Negative pregnancy test (females of child bearing potential) and use of effective
             contraceptive method (for both males and females). A pregnancy test may be performed
             on serum or urine human chorionic gonadotropin (HCG).

          6. Signed written informed consent
Clinical trial NCT00468481 (phase 3, status: completed)
Conditions: neural tube defects, contraception, oral contraceptives (oc)
ICD codes: Z92.0, Z30.012, Z30.09, T38.4X6S, T38.4X3S, T38.4X4S, T38.4X5S, T38.4X6A, T38.4X6D, Z30.40
Drugs: drospirenone/ethinylestradiol/methyltetrahydrofolate, drospirenone/ethinylestradiol (yaz)
SMILES: [H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3, [H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
Eligibility criteria:

        Inclusion Criteria:

        - Healthy women between 18 and 40 requesting oral contraception

        Exclusion Criteria:

        - The use of steroidal oral contraceptives, or any drug that could alter Oral Contraception
        metabolism will be prohibited during the study
Clinical trial NCT01197534 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: fostamatinib, fostamatinib, placebo, fostamatinib
SMILES: COC1=CC(NC2=NC=C(F)C(NC3=CC=C4OC(C)(C)C(=O)NC4=N3)=N2)=CC(OC)=C1OC, COC1=CC(NC2=NC=C(F)C(NC3=CC=C4OC(C)(C)C(=O)NC4=N3)=N2)=CC(OC)=C1OC, COC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC
Eligibility criteria:

        Inclusion Criteria:

          -  Active rheumatoid arthritis (RA) diagnosed after the age of 16

          -  Treatment with one the following disease modifying anti-rheumatic drug: methotrexate,
             sulfasalazine, hydroxychloroquine or chloroquine

          -  4 or more swollen joints and 4 or more tender/painful joints (from 28 joint count)and
             either Erythrocyte Sedimentation Rate (ESR) blood result of 28mm/h or more, or
             C-Reactive Protein (CRP) blood result of 10mg/L or more

          -  At least one of the following: documented history of positive rheumatoid factor (blood
             test), current presence of rheumatoid factor (blood test), radiographic erosion within
             12 months prior to study enrolment, presence of serum anti-cyclic citrullinated
             peptide antibodies (blood test)

        Exclusion Criteria:

          -  Females who are pregnant or breast feeding

          -  Poorly controlled hypertension

          -  Liver disease or significant liver function test abnormalities

          -  Certain inflammatory conditions (other than rheumatoid arthritis), connective tissue
             diseases or chronic pain disorders

          -  Recent or significant cardiovascular disease

          -  Significant active or recent infection including tuberculosis

          -  Previous failure to respond to a TNF alpha antagonist, anakinra or previous treatment
             with other biological agent

          -  Severe renal impairment

          -  Neutropenia
Clinical trial NCT01147848 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: fluticasone furoate/vilanterol inhalation powder, fluticasone propionate/salmeterol inhalation powder, placebo (1), placebo (2)
SMILES: OCC1=C(O)C=CC(=C1)[C@@H](O)CNCCCCCCOCCOCC1=C(Cl)C=CC=C1Cl, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of asthma

          -  Reversibility of at least 12% and at least 200mLs within 10-40 minutes following 2-4
             inhalations of albuterol

          -  FEV1 of 40-85% predicted normal

          -  Currently using inhaled corticosteroid therapy

        Exclusion Criteria:

          -  History of life-threatening asthma within previous 5 years (requiring intubation
             and/or was associated with hypercapnoea, respiratory arrest or hypoxic seizures)

          -  Respiratory infection or oral candidiasis

          -  Asthma exacerbation requiring oral corticosteroids or that resulted in overnight
             hospitalisation requiring additional asthma treatment

          -  Uncontrolled disease or clinical abnormality

          -  Allergies

          -  Taking another investigational medication or prohibited medication

          -  Night shift workers

          -  Current smokers or subjects with smoking history of at least 10 pack years
Clinical trial NCT00376584 (phase 3, status: completed)
Conditions: hypercholesteremia, hyperlipidemia
ICD codes: E78.2, E78.49, E78.5
Drugs: mk-0524a, er niacin, placebo
SMILES: OC(=O)C1=CN=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient is appropriate candidate for niacin therapy

          -  Patients with evidence of ischemic cardiovascular disease must be on a statin and have
             LDL-C <130 mg/dL at V1

          -  Patients with diabetes mellitus and no evidence of ischemic cardiovascular disease
             must have LDL-C <130 mg/dL at V1

          -  Non-diabetic patients with 2 or more risk factors for coronary heart disease and no
             ischemic cardiovascular disease must have LDL-C <160 mg/dL at V1

          -  Patient has TG <500 mg/dL (5.65 mmol/L) at V1

          -  A patients historic serum or plasma lipid values measured within 6 months from Visit 1
             may be used to meet lipid inclusion criteria

          -  ALL OTHER PATIENTS DO NOT REQUIRE SPECIFIC LIPID ENTRY CRITERIA

        Exclusion Criteria:

          -  Patients with unstable doses of medications

          -  Pregnant or lactating women, or women intending to become pregnant are excluded

          -  Patients with diabetes mellitus that is poorly controlled, unstable or newly diagnosed

          -  Patients with: chronic heart failure, uncontrolled/unstable cardiac arrhythmias,
             unstable hypertension, active or chronic hepatobiliary disorder or hepatic disease,
             HIV positive, gout (within 1 year)
Clinical trial NCT01171976 (phase 3, status: completed)
Conditions: diabetic macular edema
ICD codes: E10.311, E10.319, E11.311, E11.319, E13.311, E13.319, E10.3513
Drugs: ranibizumab
SMILES: CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

        Patient

          -  Patients with Type 1 or Type 2 diabetes mellitus (according to American Diabetes
             Association or World Health Organization [WHO] guidelines) with glycosylated
             hemoglobin (HbA1c) ≤ 12.0% at screening (Visit 1). Patients should be on diet,
             exercise, and/or pharmacological treatment for diabetes. Treatment for diabetes must
             have been stable for at least 3 month.

        Ocular

          -  Patients with visual impairment due to DME in at least one eye who are eligible for
             laser treatment in the opinion of the investigator. If both eyes are eligible, the one
             with the worse visual acuity, as assessed at Visit 1, will be selected by the
             investigator as the study eye.

          -  BCVA ≥ 39 and ≤78 letters in the study eye and, inclusively, using Early Treatment
             Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing
             distance of 4 meters (approximate Snellen equivalent of 20/32 to 20/160) at screening.

          -  Concomitant conditions in the study eye are only permitted if, in the opinion of the
             investigator, they do not prevent improvement of visual acuity on study treatment.

        Exclusion Criteria:

        Patient Compliance/ Administrative

          -  Pregnant or nursing (lactating) women.

        Ocular medical history

          -  Active intraocular inflammation (grade trace or above) in either eye at enrollment.

          -  Any active infection (e.g. conjunctivitis, keratitis, scleritis, uveitis,
             endophthalmitis) in either eye at the time of enrollment.

          -  History of uveitis in either eye at any time.

          -  Structural damage within 0.5 disc diameter of the center of the macular in the study
             eye likely to preclude improvement in visual acuity following the resolution of
             macular edema.

          -  Uncontrolled glaucoma in either eye at screening.

        Prior Ocular treatments

          -  Panretinal laser photocoagulation in the study eye within 6 months prior to
             randomization.

          -  Focal/grid laser photocoagulation in the study eye within 3 months prior to
             randomization.

          -  Treatment with anti-angiogenic drugs in either eye.

        Systemic conditions or treatments

          -  History of stroke within 6 months prior to enrollment.

          -  Renal failure requiring dialysis.

          -  Untreated diabetes mellitus.

          -  Blood pressure systolic > 160 mmHg or diastolic > 100 mmHg.

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00338650 (phase 3, status: completed)
Conditions: crohn's disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: adalimumab
SMILES: O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient diagnosed with moderate to severe Crohn's Disease.

          -  Failed prior infliximab therapy.

          -  Patient is judged to be in generally good health as determined by the principal
             investigator.

        Exclusion Criteria:

          -  Previous treatment with adalimumab.

          -  Patient considered by the investigator, for any reason, to be an unsuitable candidate
Clinical trial NCT01167881 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: bi 10773, glimepiride, placebo, placebo
SMILES: [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  Diagnosis typ 2 diabetes mellitus

          -  Male and female on diet and exercise regimen, pre-treated with metformin 12 weeks
             prior to randomisation

          -  HbA1c equal or greater than 7.0% and less than or equal to 10% at visit 1

          -  18 years or more

          -  BMI equal or less than 45Kg/m2

        Exclusion criteria:

          -  Uncontrolled hyperglycemia defined as glucose more that 13.3 mmol/L after overnight
             fast during placebo run-in

          -  Any other antidiabetic drug within 12 weeks prior to randomisation except metformin

          -  Acute coronary syndrome (non-STEMI, STEMI unstable angina pectoris), stroke or
             transient ischemic attack within 12 weeks of informed consent

          -  Indication of liver disease

          -  Moderate to severe renal impairment

          -  Bariatric surgery within past 2 years

          -  Medical history of cancer or treatment for cancer within last 5 years

          -  Blood dyscrasias or any disorders causing haemolysis or unstable red blood cell

          -  Contraindications hypersensitivity to concomitant drugs

          -  Treatment with anti-obesity drugs
Clinical trial NCT00099736 (phase 3, status: completed)
Conditions: kidney transplantation
ICD codes: N26.2, Q63.0, Q63.2, Z52.4, I75.81, N19, N20.0
Drugs: fty720 5 mg + reduced-dose neoral (rdn) + corticosteroids, fty720 2.5 mg + full dose neoral (fdn) + corticosteroids, mmf 2 g + full-dose neoral (fdn) + corticosteroids
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  First kidney transplantation

          -  Male and female patients

          -  Between 18 and 65 years old

        Exclusion Criteria:

          -  Patients in need of multiple organ transplants
Clinical trial NCT00401245 (phase 3, status: completed)
Conditions: vasomotor symptoms
ICD codes: J30.0
Drugs: desvenlafaxine succinate sustained release, desvenlafaxine succinate sustained release, desvenlafaxine succinate sustained release, desvenlafaxine succinate sustained release, placebo, desvenlafaxine succinate sustained release, desvenlafaxine succinate sustained release, desvenlafaxine succinate sustained release
SMILES: CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1, CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1, CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1, CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1, CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1, CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Generally healthy, postmenopausal woman who seeks treatment for hot flushes.

          -  Meets 1 of the following: At least 12 months of spontaneous amenorrhea; At least 6
             months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels
             > 40 mIU/mL; At least 6 weeks postsurgical bilateral oophorectomy (with or without
             hysterectomy). Hysterectomized without bilateral oophorectomy and with serum FSH
             levels >40 mIU/mL.

        Exclusion Criteria:

          -  History of a seizure disorder other than a single childhood febrile seizure.

          -  History or presence of clinically important hepatic or renal disease or other medical
             disease.

          -  Presence or recent history of major depressive disorder, bipolar disorder, psychotic
             disorder, or generalized anxiety disorder requiring therapy.
Clinical trial NCT00078988 (phase 3, status: completed)
Conditions: brain tumor, central nervous system tumor
ICD codes: C71.7, C71.9, C79.31, D33.0, D33.1, D33.2, D49.6
Drugs: carboplatin, etoposide, isotretinoin, thiotepa
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O, CN(C)CCOC(C)(C1=CC=CC=C1)C1=CC=CC=N1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed diagnosis of 1 of the following high-grade gliomas:

               -  Glioblastoma multiforme

               -  Anaplastic astrocytoma

               -  Gliosarcoma

          -  Disease in first relapse

          -  No primary brainstem or spinal cord gliomas

          -  No secondary glioblastomas arising after prior treatment for a non-glial tumor

          -  Prior local radiotherapy of 5,000-6,000 cGy required

          -  Less than 1.5 cm of residual gadolinium-enhancing tumor in maximal cross-sectional
             diameter by MRI

          -  No metastatic tumor by spinal MRI

        PATIENT CHARACTERISTICS:

        Age

          -  Under 21 at diagnosis

        Performance status

          -  Lansky 50-100% OR

          -  Karnofsky 50-100%

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Absolute neutrophil count ≥ 500/mm^3

          -  Platelet count ≥ 100,000/mm^3 (transfusion independent)

        Hepatic

          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  AST or ALT < 2.5 times ULN

        Renal

          -  Glomerular filtration rate ≥ 60 mL/min AND/OR

          -  Creatinine clearance ≥ 60 mL/min

        Cardiovascular

          -  Shortening fraction ≥ 27% by echocardiogram OR

          -  Ejection fraction ≥ 50% by MUGA

        Pulmonary

          -  No dyspnea at rest

          -  No exercise intolerance

          -  Pulse oximetry > 94%

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  More than 4 weeks since prior chemotherapy

          -  No prior thiotepa

          -  No prior myeloablative chemotherapy

        Endocrine therapy

          -  No concurrent corticosteroids

        Radiotherapy

          -  See Disease Characteristics

          -  More than 8 weeks since prior radiotherapy

          -  No prior craniospinal radiotherapy

        Surgery

          -  Not specified
Clinical trial NCT00109044 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: escitalopram
SMILES: CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must meet Diagnostic and Statistical Manual, Fourth Edition (DSM-IV)
             diagnostic criteria for Major Depressive Disorder.

          -  The patient's current depressive episode must be at least 12 weeks in duration.

        Exclusion Criteria:

          -  Women who are pregnant, women who will be breastfeeding during the study, and women of
             childbearing potential who are not practicing a reliable method of birth control.

          -  Patients who currently meet DSM-IV criteria for: a. bipolar disorder; b. schizophrenia
             or any psychotic disorder; c. obsessive-compulsive disorder; d. mental retardation or
             any pervasive developmental disorder or cognitive disorder.

          -  Patients who are considered a suicide risk.

          -  Patients with a history of seizure disorder, or any history of seizure, stroke,
             significant head injury, or any other condition that predisposes toward risk of
             seizure.
Clinical trial NCT00311753 (phase 3, status: completed)
Conditions: embolism
ICD codes: I27.82, I76, O88.02, O88.82, T79.0XXS, T79.1XXS, O03.2
Drugs: certoparin, heparin
SMILES: O.O.[Al+3].[Cl-].[Zr+4].NCC([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Hospitalization due to an acute non-surgical disease

          -  Significant decrease in mobility

        Exclusion Criteria:

          -  Indication for anticoagulant or thrombolytic therapy

          -  Major surgical or invasive procedure within the 4 weeks that precede randomization

          -  Expected major surgical or invasive procedure (including spinal/peridural/epidural
             anesthesia or lumbar puncture) within the 2 weeks that follow the randomization

          -  Immobilization due to cast or fracture of lower extremity

          -  Immobilization lasting longer than 3 days in the period prior to randomization

          -  Heparin administration longer than 36 hours in the period prior to randomization

          -  Acute ischemic stroke

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00726375 (phase 3, status: completed)
Conditions: acute graft versus host disease
ICD codes: D89.810, D89.812
Drugs: etanercept (enbrel)
SMILES: [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          1. Patient must have undergone HCT (donor cells from any source) with either a
             myeloablative or nonmyeloablative preparative regimen.

          2. Patient may be any age.

          3. Patient must have biopsy-proven Grade I acute GVHD (Appendix A). Biopsy report does
             not have to be back from Pathology prior to enrollment. Patients whose biopsy for GVHD
             identifies pathology inconsistent with GVHD will be removed from the study and
             replaced. However, because GVHD is a clinical diagnosis, biopsies which are
             non-diagnostic or do not show a clear non-GVHD etiology will not be cause to remove
             the patient from the study.

        Exclusion Criteria:

          1. Patients who are pregnant (positive urine or serum test) or nursing.

          2. Active infections which are unresponsive to antibiotics (> 2 consecutive [at least 24
             hours apart], positive blood cultures after initiation of treatment).

          3. Allergic or otherwise undesirable reaction to etanercept.

          4. Use of any oral or intravenous steroids at any previous time for GVHD treatment. Prior
             use of steroid therapy (i.e. hydrocortisone) as pre-medication for transfusions is
             permissible. Prior use of topical steroids is allowed.

          5. Use of etanercept for any other purpose.

          6. Noncompliance with medications.

          7. Grade II-IV GVHD (history of or at time of study entry).